News
27 March 2025
The development of new therapeutics depends on the ability to identify compounds that interact with specific molecular targets involved in disease pathways. Target-based screening has become […]
4 March 2025
The field of drug discovery faces a critical challenge: despite their vast therapeutic potential, many G Protein-Coupled Receptors (GPCRs) remain unexplored. These receptors play a fundamental […]
21 February 2025
Studying receptor-ligand interaction is a crucial approach in drug discovery and biomedical research. Radioligands have been the gold standard for binding assays since their first use […]
16 January 2024
We are very proud to present our last paper in collaboration with the Institute of Neuroscience of the Universitat de Barcelona, the CiQUS – Center for Research in […]
18 October 2023
Sigma (σ) receptor subtypes, σ1 and σ2, are targets of wide pharmaceutical interest. σ1 receptor ligands are under evaluation in clinical trials for the treatment of diseases such as […]
11 September 2023
A major bottleneck in drug discovery, particularly when targeting transmembrane proteins such as G-coupled receptor proteins (GPCRs), is the challenge of replicating in vitro the precise microenvironment conditions […]
19 July 2023
Traditional pharmacological mechanisms leave a significant part of the genome ‘undruggable’, due to the inability to induce or block their activity using agonists and antagonists. Thanks […]
13 July 2023
Celtarys expands its presence in the GPCR field, developing new applications in collaboration agreement with Nanotemper, a company devoted to the development of innovative instruments for […]
10 July 2023
The fabrication of a particular device depends heavily on the immobilization of the biosensing element (a probe such as an antibody, aptamer, etc.) onto the transducer […]